Jaguar Health Secures U.S. License Deal with Future Pak for Crofelemer

Jaguar Health, Inc. has entered a U.S. licensing agreement with Future Pak, granting the latter exclusive marketing rights for Mytesi® and Canalevia®-CA1. Jaguar will receive an $18 million upfront payment and up to an additional $20 million in future milestones. This deal allows Jaguar to focus on its rare-disease pipeline while maintaining manufacturing duties.

Future Pak, already strong in the U.S. HIV market, will now market Mytesi, an FDA-approved drug for noninfectious diarrhea in HIV/AIDS patients, and Canalevia-CA1, used for chemotherapy-induced diarrhea in dogs. The agreement also gives Jaguar the option to reacquire these rights under specific conditions.

Jaguar continues clinical studies on crofelemer for rare diseases, hoping for significant regulatory milestones. The funds and strategic partnership are anticipated to aid Jaguar's focus on advancing treatments for rare conditions.